Uncategorized

Grammy Hall of Fame member Peter Frampton headed to Windsor

Grammy Hall of Fame member Peter Frampton headed to Windsor

Published Dec 02, 2023  •  1 minute read

Peter Frampton
Peter Frampton performs onstage at the TEC Awards during the 2019 NAMM Show at the Hilton Anaheim on January 26, 2019 in Anaheim, California. Photo by Jesse Grant /Getty Images for NAMM

Legendary guitarist and rocker Peter Frampton is planning a stop in Windsor as he celebrates 60 years of shows with the Never Ever Say Never tour.

The new tour, which follows a string of unexpected spring and summer shows in 2023, will see Frampton hitting stages across North America.

Article content

He announced his farewell tour four years ago following a diagnosis of the degenerative disease inclusion-body myositis.

Advertisement 2

Windsor Star

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

  • Unlimited online access to articles from across Canada with one account.
  • Get exclusive access to the Windsor Star ePaper, an electronic replica of the print edition that you can share, download and comment on.
  • Enjoy insights and behind-the-scenes analysis from our award-winning journalists.
  • Support local journalists and the next generation of journalists.
  • Daily puzzles including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

  • Unlimited online access to articles from across Canada with one account.
  • Get exclusive access to the Windsor Star ePaper, an electronic replica of the print edition that you can share, download and comment on.
  • Enjoy insights and behind-the-scenes analysis from our award-winning journalists.
  • Support local journalists and the next generation of journalists.
  • Daily puzzles including the New York Times Crossword.

REGISTER TO UNLOCK MORE ARTICLES

Create an account or sign in to continue with your reading experience.

  • Access articles from across Canada with one account.
  • Share your thoughts and join the conversation in the comments.
  • Enjoy additional articles per month.
  • Get email updates from your favourite authors.

Article content

“I am delighted to let you know I’m planning more shows in March and April for the new Never Ever Say Never Tour,” Frampton said in a media release. “I don’t want to give up my passion and will play as long as I physically can. Hope to see you in 2024.”

Frampton is bringing in his Never Ever Say Never Tour to The Colosseum stage at Caesars Windsor on March 15.

Citi card members will have access to presale tickets in select cities from 10 a.m. on Dec. 4 to 10 p.m. on Dec. 7. Go to citientertainment.com for details.

Another pre-sale for Caesars Rewards members will begin at 10 a.m. on Dec. 6.

The general ticket sale begins Dec. 8 at 10 a.m.

Tickets will be available caesarswindsor.com or ticketmaster.ca.

The Caesars box office is also open from 12 p.m. to 8 p.m. on Friday and Saturday, and 12 p.m. to 10 p.m. on show days.

[email protected]

Article content

Read More

iS Prime, SEC, ARGO and Nomura: Executive Moves of the Week

iS Prime, SEC, ARGO and Nomura: Executive Moves of the Week

This week marks significant shifts in the forex, crypto, and fintech industries, signaling a dynamic transformation in the financial technology landscape.

Key executive moves include Matteo Paganini’s appointment as Group Chief Commercial Officer at ActivTrades and Hanna Chung’s role as XS.com’s Vietnam Country Manager. The FCA’s Competition Decisions Committees see crucial additions, while Tools for Brokers’ management undergoes strategic reshuffles. Additionally, oneZero witnesses pivotal changes in leadership, Chris de Sibert joins AlpFin, and Phil Hermon advances at CME Group.

Explore these noteworthy executive transitions in the forex, crypto, and fintech sectors as we delve into the evolving leadership landscape of financial technology. Stay informed about the latest developments in these dynamic industries.

Jonathan Brewer

Jonathan Brewer

iS Prime’s Former Partner Jonathan Brewer Moves to Evolving
Mind

Jonathan Brewer, previously the Managing Partner at iS Prime Ltd, has taken on a new role as an Investor and Advisor at The Evolving Mind. This organization specializes in identifying and supporting children with special educational needs and neurodiversity, as noted by Brewer on his LinkedIn profile.

Brewer’s career history includes significant roles in the financial industry, including his tenure at iS Prime, where he served as Managing Director, Founding Partner, and Commercial Director for over eight years. Before that, he worked as the Head of eFX Sales at Sucden Financial and held an Associate position at Goldman Sachs, where he was involved in sales of electronic trading and clearing services for listed derivatives and FX to top-tier institutions across various sectors.

SEC-logo

SEC Appoints Kate E. Zoladz as Regional Director in Los Angeles

The Securities and Exchange Commission (SEC) has announced the appointment of Kate E. Zoladz as the Regional Director of its Los Angeles Office, effective from December 3, 2023. Zoladz, a seasoned professional who has been with the SEC since 2010 and previously served as the Associate Regional Director for Enforcement, will lead a team responsible for securities enforcement and compliance in several western US regions.

Kate Zoladz’s extensive background in securities litigation and compliance positions her as a valuable asset in the SEC’s mission to safeguard investors. Her appointment reflects the SEC’s commitment to upholding regulatory standards and protecting the interests of the investing public.

Argo

Argo Blockchain Welcomes
New CEO

Argo Blockchain PLC has announced the appointment of Thomas Chippas as its new Chief Executive Officer. Chippas, with a substantial background in digital assets and financial services, brings a wealth of experience to Argo. His impressive career includes notable positions at CBOE Digital, Citadel Technology LLC, and several major banks.

“Tom
is a proven technology and financial leader who will work with the Argo
leadership team to drive operational excellence and stakeholder value,” Matthew
Shaw, the Chairman of Argo commented.

The arrival of Chippas signifies Argo Blockchain’s commitment to leadership with deep expertise in the digital asset and financial sectors. His extensive industry knowledge positions him to steer the company towards continued success and growth.

Nomura

Nomura Strengthens QIS
Team with New Appointment

Nomura International plc has appointed Jérôme Brochard as the Global Head of QIS Structuring and EMEA Head of QIS Distribution. Brochard, a seasoned professional with more than 25 years of industry experience, comes to Nomura from Credit Suisse. In his new role, he will lead the development and distribution of Nomura’s Quantitative Investment Strategies (QIS), aligning with the company’s strategic initiative to diversify its product offerings and enhance client engagement in the QIS domain.

John Goff, the Global Head of Structuring at Nomura, expressed confidence in Brochard’s extensive experience and expertise in quantitative investment strategies, highlighting how this appointment positions Nomura for greater capabilities and enhanced client relations in the QIS field.

This week marks significant shifts in the forex, crypto, and fintech industries, signaling a dynamic transformation in the financial technology landscape.

Key executive moves include Matteo Paganini’s appointment as Group Chief Commercial Officer at ActivTrades and Hanna Chung’s role as XS.com’s Vietnam Country Manager. The FCA’s Competition Decisions Committees see crucial additions, while Tools for Brokers’ management undergoes strategic reshuffles. Additionally, oneZero witnesses pivotal changes in leadership, Chris de Sibert joins AlpFin, and Phil Hermon advances at CME Group.

Explore these noteworthy executive transitions in the forex, crypto, and fintech sectors as we delve into the evolving leadership landscape of financial technology. Stay informed about the latest developments in these dynamic industries.

Jonathan Brewer

Jonathan Brewer

iS Prime’s Former Partner Jonathan Brewer Moves to Evolving
Mind

Jonathan Brewer, previously the Managing Partner at iS Prime Ltd, has taken on a new role as an Investor and Advisor at The Evolving Mind. This organization specializes in identifying and supporting children with special educational needs and neurodiversity, as noted by Brewer on his LinkedIn profile.

Brewer’s career history includes significant roles in the financial industry, including his tenure at iS Prime, where he served as Managing Director, Founding Partner, and Commercial Director for over eight years. Before that, he worked as the Head of eFX Sales at Sucden Financial and held an Associate position at Goldman Sachs, where he was involved in sales of electronic trading and clearing services for listed derivatives and FX to top-tier institutions across various sectors.

SEC-logo

SEC Appoints Kate E. Zoladz as Regional Director in Los Angeles

The Securities and Exchange Commission (SEC) has announced the appointment of Kate E. Zoladz as the Regional Director of its Los Angeles Office, effective from December 3, 2023. Zoladz, a seasoned professional who has been with the SEC since 2010 and previously served as the Associate Regional Director for Enforcement, will lead a team responsible for securities enforcement and compliance in several western US regions.

Kate Zoladz’s extensive background in securities litigation and compliance positions her as a valuable asset in the SEC’s mission to safeguard investors. Her appointment reflects the SEC’s commitment to upholding regulatory standards and protecting the interests of the investing public.

Argo

Argo Blockchain Welcomes
New CEO

Argo Blockchain PLC has announced the appointment of Thomas Chippas as its new Chief Executive Officer. Chippas, with a substantial background in digital assets and financial services, brings a wealth of experience to Argo. His impressive career includes notable positions at CBOE Digital, Citadel Technology LLC, and several major banks.

“Tom
is a proven technology and financial leader who will work with the Argo
leadership team to drive operational excellence and stakeholder value,” Matthew
Shaw, the Chairman of Argo commented.

The arrival of Chippas signifies Argo Blockchain’s commitment to leadership with deep expertise in the digital asset and financial sectors. His extensive industry knowledge positions him to steer the company towards continued success and growth.

Nomura

Nomura Strengthens QIS
Team with New Appointment

Nomura International plc has appointed Jérôme Brochard as the Global Head of QIS Structuring and EMEA Head of QIS Distribution. Brochard, a seasoned professional with more than 25 years of industry experience, comes to Nomura from Credit Suisse. In his new role, he will lead the development and distribution of Nomura’s Quantitative Investment Strategies (QIS), aligning with the company’s strategic initiative to diversify its product offerings and enhance client engagement in the QIS domain.

John Goff, the Global Head of Structuring at Nomura, expressed confidence in Brochard’s extensive experience and expertise in quantitative investment strategies, highlighting how this appointment positions Nomura for greater capabilities and enhanced client relations in the QIS field.

Read More

Managing the Safety of Newer Atopic Dermatitis Treatments

Managing the Safety of Newer Atopic Dermatitis Treatments

MedPage Today brought together three expert leaders for a virtual roundtable discussion on atopic dermatitis : Moderator Peter Lio, MD, of Northwestern University Feinberg School of Medicine in Chicago, is joined by Linda Stein Gold, MD, of the Henry Ford Health System in Detroit, and Alexandra Golant, MD, of the Icahn School of Medicine at Mount Sinai in New York City.

This third of four exclusive episodes explores safety monitoring of treatments for the condition. Click here to watch other videos from this roundtable series.

Following is a transcript of their discussion:

Lio: This brings us to our third question, which is really all about the pitfalls and the monitoring, and this is a perfect segue. So Dr. Golant, I’ve heard you talk very beautifully before on the black box warning on the JAK [Janus kinase] inhibitors, and I’m wondering if you could sort of summarize that for us here, what you might say to your patient when they say, “But doesn’t this have a scary warning on it? What am I supposed to do with this?”

Golant: That’s a great question, and I’ve heard you speak beautifully on it too, so I’d be curious to know how you deliver it. But I generally say that, “this entire class of medication,” including the topical that’s approved or topical JAK inhibitor that Linda mentioned, ruxolitinib [Opzelura], “has a boxed warning. This came from a higher risk patient population with a different JAK inhibitor that was thought to be more immunosuppressive.”

“But in that study there was a higher rate of,” and I go through the five kind of categories that are on that box warning, which are infection, mortality, cardiovascular events, clots, and malignancy. Then I say, “In the actual clinical trials of this medication I’m talking to you about in an atopic dermatitis population, what seemed to be a true signal, meaning thought to have correlation or cause-effect with the drug in a patient like you, really was limited to infections, particularly shingles and non-melanoma skin cancer.”

That conversation lives best after having taken a really detailed history from your patients. So to Linda’s point, are they 65 and up? Have they had a cardiovascular event or unprovoked clot? Are they a smoker? What else is going on in their life? Do they have an active malignancy? There are definitely buckets where you would think twice. I liked how Linda said that it’s not a “never use,” it’s a “use your best judgment” and sometimes reach out to the other care teams to get their thoughts about it too. That’s kind of how I approach it usually.

Lio: I couldn’t agree more, and I love that idea that it’s — forced is strong, but it’s true — it’s forced me to reach out to other care team members, which I think in dermatology we don’t like to do as much. We tend to be kind of an island and we don’t really love communicating as much as we should, but it has been great. I’ll talk to the cardiologist, I’ll talk to the oncologist. I’ll say, “Listen, this is where we’re at. These are our options.” And I think for some patients the answer is going to be, no, we have to do something else, but for others it’s going to be this still is the best choice, even though yes, there may be a higher risk profile, but we’re going to do monitoring.

So Dr. Stein Gold, I’ll turn it over to you. What, and understanding that the JAK inhibitor guidelines for monitoring, of course these are for the oral agents; there’s no specific monitoring recommended for the topical ruxolitinib. But for the orals, it’s a little bit vague; they give us kind of a leash. So I’m just curious personally, how do you usually go about it and what kinds of things are you thinking about when you’re telling a patient how you’re going to monitor?

Stein Gold: And I think that the fact that it’s a little bit loose is a good thing, and because it might be different for each patient depending on their particular history, but I do get complete … monitoring at baseline. You want to make sure their patients are not pregnant. You advise them it’s not a good idea to get pregnant while taking an oral JAK inhibitor. Certainly the TB [tuberculosis] tests. But all baseline labs are done initially. And then you can look… and I’ve learned that all these young healthy people who come into your office are not young, healthy people. You pick up a lot of things on baseline labs that patients had no idea that they had. So I think that baseline monitoring is a great thing for patients in general.

And then often what I’ll do, it depends really. With one of the oral medications, we can start to see changes within the first month, with the other one, it’s within the first 3 months. So it really depends. But what I’ve found is, similar to what we did in the clinical trials — and we’ve studied all of these agents in clinical trials so I’m fairly comfortable seeing these agents over the course of many years at this point — but I’ll tend to monitor heavier upfront, maybe at baseline, and then 3 months and then another 3 months, then see where things go. But in general, I’ll probably, if somebody is on the medication and stable, I might check blood work twice a year.

Lio: That is so helpful, and it’s just so great to have your wisdom and experience because I mean, obviously you treat a lot of serious dermatologic conditions and JAK inhibitors are a powerful member of this family. But maybe they’re not even the most dangerous. I often think about how prednisone, cyclosporine, methotrexate, azathioprine, those are pretty big guns too, and arguably in some ways more dangerous than the JAKs. So we have this sort of apples to oranges. But I also don’t want to totally blow over the biologics. I kind of said the biologics are an easier sell, but as you pointed out, they’re not always an easy sell. Maybe easier but not easy.

So Dr. Golant, when you’re talking to a patient about biologics, what kinds of safety and tolerability points do you bring up? And people still ask me this to this day — I don’t do any monitoring, but, do you or is there any monitoring you would do for a biologic patient?

Golant: I do not do any monitoring, and that was a departure for me. When they first were approved, I was doing monitoring just because I was so used to doing monitoring with our biologics for which we had biologics for psoriasis at that point, and then you end up finding things that don’t preclude you from using the medication. So I said, no more. And that’s per their label, right? I really do feel strongly we should be listening to the label. No immunosuppression, no box warning, no monitoring.

I think for both classes, for biologics and the JAK inhibitors, the patient’s understanding of why you’re talking to them about these medications lands best when you explain why we’re talking to you about a systemic medication in general, because we understand atopic dermatitis is a systemic disease. And just like any other chronic condition — high cholesterol, hypertension, you name it — sometimes we need to intervene in a systemic way. That is usually my transition point to saying this is our menu. When I counsel about the biologics, usually from a risk or safety profile, I do mention no immunosuppression; this is not a steroid, probably like you’ve had before. Most of our biologics come with some elevated risk of not just conjunctivitis, but just overall ocular symptomatology: dry eye, itchy eye, irritated eye, red eye. So I talk through that. Sometimes I’ll mention slight increase in herpes viral infections, which we’re seen in many of the trials. Injection site reactions certainly.

But once you get to safety with the biologics, like you said, Peter, there’s not that much to speak about. So that part usually goes pretty quickly once they have the buy-in of “Why are you talking to me about this medication in the first place?”

Lio: I love it. And since we have a couple of extra minutes, I’d love to just pick your brain. So you mentioned the eye issue, so conjunctivitis, keratitis, eye pruritus, dry eye, blepharitis, we see that kind of cluster. What about the face and neck dermatitis? Are you seeing that a lot?

Stein Gold: I don’t see it that commonly, but I certainly do see it. And I have had patients that… and that’s the reason why I have to take them off their biologic agent, and that’s a time when I might consider going to an oral JAK. Because facial dermatitis can be really a problem. It’s something that they think about every day. They walk into a room, their face is red, their eyes might be kind of red and swollen. It can be an issue. Again, I don’t see it that commonly, but when I do see it, often it is an issue.

Golant: Yeah, I was just going to say I completely agree, and when I have a patient with predominant disease on the head and the neck, I will often say, especially for the biologics, “The trickiest areas to clear sometimes is this part of you [indicates face and neck]. So this is our starting point, but know there are other options if this doesn’t become our final solution.”

Lio: And then on the other side, with the JAKs, what are kind of the common things that come up? Dr. Stein Gold? Do you feel that the acne, and are there some other things that maybe are more tolerability things that might pop up for a patient?

Stein Gold: You think about the acne, the headache, a little bit of nausea early on, but for most of my patients, they really tolerate it quite well.

But I want to go back to one thing that you brought up. So I’m not sure what the incidence of the facial erythema is going to be with our newer biologic agents, with tralo [tralokinumab; Adbry] and with lebri [lebrikizumab]. I haven’t seen it yet in my clinical trials with either of those or with lebri in real life. So that’s something I think is still a little bit up in the air.

Lio: That is one of the most compelling things too because right, we’ve kind of lumped everything together, but they really are different drugs, and particularly the biologics. I mean, they’re binding in slightly different areas, so dupilumab, tralo, and lebri, they’re all the same pathway, but not fully, right? [Dupilumab] gets the IL-4 as well, so I’ll be curious. It seems like the conjunctivitis signal is out there, and now it may be differential in terms of how common it is, but it seems like clinically it’ll be comparable, but the face and neck maybe will be different, which would be wild.

For the JAKs, I feel like, again, they’re pretty similar, but they’re also different drugs. So yeah, I think that there may be some… I wish we had more biomarkers. I wish we had more insight into this so we could give more precision approach, but right now, I don’t think it’s crazy when someone says, “I failed this biologic, can I try another?” It’s not necessarily ridiculous. They’re not truly the same, especially if they’ve responded — at least in my experience — if they’ve responded to it in terms of their eczema but maybe had an adverse event, then I think it could definitely be worth switching to another biologic. If they didn’t respond at all, then I feel like maybe it’s time to switch categories and go to the JAK inhibitor. Would you guys agree with that?

Golant: I would. I would also add that I’ve seen the similar or same thing with the JAK inhibitors. I’ve seen a patient that might’ve had a partial not complete response to one, do very, very well on the other. So that surprised me too.

Stein Gold: Yeah, I think we’re still learning so much, and I think the longer these medications are available, the more we’ll truly understand. There have been some case reports of patients who were non-responders on one biologic or responded to the other one, but I think time will tell and we’ll really get a better handle on how to approach these patients.

Lio: I love it.

  • author['full_name']

    Greg Laub is the Senior Director of Video and currently leads the video and podcast production teams. Follow

Read More

Anthony Pettis picks ‘pioneer’ B.J. Penn as lightweight GOAT: ‘Without B.J., none of this would even be possible’

Anthony Pettis picks ‘pioneer’ B.J. Penn as lightweight GOAT: ‘Without B.J., none of this would even be possible’


B.J. Penn

Anthony Pettis thinks B.J. Penn was instrumental in building the lightweight division.

Pettis, a former WEC and UFC lightweight champion, listed his top five greatest lightweights of all time.

His No. 1 pick was former champion Penn, who defended his UFC lightweight title three times with finishes of Sean Sherk, Kenny Florian and Diego Sanchez. Penn also is a former UFC welterweight champion

“(I’ve) got to go B.J. Penn,” Pettis said in an interview with Low Kick MMA. “I mean, B.J. Penn is one of the pioneers of the whole thing. Without B.J., none of this would even be possible. Ben Henderson’s in my top five, as well. You’ve got to go with Khabib (Nurmagomedov). He’s definitely on there – a dominant guy, never lost. Dustin Poirier is another guy that’s on my top-five list, and then I would take myself.”

Pettis thinks it’s too early to include current UFC lightweight champion Islam Makhachev, but thinks he has all the potential to become an all-time great.

“He still has some work to do,” Pettis said. “He just beat (Alexander) Volkanovski, and Volkanovski is an amazing fighter – but he’s not a lightweight. He doesn’t have any wins against a top-10 lightweight, so I think once he can prove himself – he’s a tremendous fighter, but he still has some work to do.

“That’s the hard thing. Once you get to the top, things change. You’ve got sponsors pulling you, you’ve got events, you’ve got promotions, you’ve got a lot of other options besides training. … Seeing how he can balance that and see when he fights and how dominant he is, that’s when we’ll see how great he can be.”

Pettis, who dethroned Henderson twice, once to become WEC champion, and again to become UFC lightweight champ, meets “Bendo” for a third time in combat sports in the Karate Combat 43 headliner on Dec. 15 at the Expo at World Trade Market in Las Vegas. Their contest will take place at 170 pounds.

Be sure to visit the MMA Junkie Instagram page and YouTube channel to discuss this and more content with fans of mixed martial arts.

Read More

Family furious after dog’s shock death at pet hotel

Article Image

Family furious after dog’s shock death at pet hotel

A devastated family is demanding answers after their beloved German shepherd Nahla died from heatstroke after staying at an Adelaide dog kennel.

Get a read on this story

Subscribe today to unlock it and more…

Article Image

Family furious after dog’s shock death at pet hotel

A devastated family is demanding answers after their beloved German shepherd Nahla died from heatstroke after staying at an Adelaide dog kennel.

Full Digital Access $4 FOR THE FIRST 4 WEEKS

Conditions apply.*

Hero Offer

Full Digital Access $4 FOR THE FIRST 4 WEEKS

Conditions apply.*

  • No lock-in contract
  • Unlimited articles on web & app
  • Subscriber-exclusive news emails

App or digital edition only customer? To upgrade, call 1300 MY NEWS (696 397)

Full Digital Access

$4 FOR THE FIRST 4 WEEKS*

Features

Offer Image

Full Digital Access

$4 FOR THE FIRST 4 WEEKS*

Features

then$7/WEEK

($28 min. cost) charged every 4 weeks.*

($28 min. cost) charged every 4 weeks.*

  • No lock-in contract
  • Unlimited articles on web & app
  • Subscriber-exclusive news emails
  • Enjoy games & puzzles
  • A digital version of Today’s Paper

Full Digital Access

12 MONTH PLAN*

Features

Offer Image

Full Digital Access

12 MONTH PLAN*

Features

$4/WEEK

for the first 12 months

$16 charged every 4 weeks (min. cost $208). Then $16 charged every 4 weeks.*

for the first 12 months

$16 charged every 4 weeks (min. cost $208). Then $16 charged every 4 weeks.*

  • Lock in & save
  • Unlimited articles on web & app
  • Subscriber-exclusive news emails
  • Enjoy games & puzzles
  • A digital version of Today’s Paper

Offer Image

$4/WEEK

($16 min. cost) charged every 4 weeks.*

($16 min. cost) charged every 4 weeks.*

  • No lock-in contract
  • 30 articles on web every 4 weeks
  • Subscriber-exclusive news emails

Full Digital Access


$4 FOR THE FIRST 4 WEEKS*

Pay Now:

$4

Selected Offer Image

Full Digital Access


$4 FOR THE FIRST 4 WEEKS*

Pay Now:

$4

  • Payment Information
  • Payment for the first 4 weeks
    $4
  • Payment every 4 weeks after that
    $28

Today’s total

$4

Read More

Pick up an Asus ROG Ally for under $400 at Best Buy

Pick up an Asus ROG Ally for under $400 at Best Buy

Asus ROG Ally - front

Image: Anyron Copeman / Foundry

, Staff Writer

Michael is a former graphic designer who’s been building and tweaking desktop computers for longer than he cares to admit. His interests include folk music, football, science fiction, and salsa verde, in no particular order.

Read More

Lockdown Soucek continues his resurgence as disjointed West Ham do just enough

Lockdown Soucek continues his resurgence as disjointed West Ham do just enough

For 88 minutes, this was the sort of Europa League performance that fans of every English team to have graced this competition have seen over and over again.

Spurs, Arsenal, Liverpool, Manchester United and Chelsea fans would all recognise the core elements. The multiple changes. The disjointedness. A hotch-potch of regular starters and fringe players trying and failing to locate a matching wavelength. The opposition raising their game for one of their biggest ever nights.

Then Tomas Soucek did what Tomas Soucek once again does, and pounced to score his second late winner in five days. The late turnaround at Burnley was a huge boost for the Hammers, and this opportunistic, striker’s finish to finally break TSC in Serbia could be huge for David Moyes’ side.

First and most obviously, they are now guaranteed to be in this competition after Christmas. That’s pretty important. But they now have the upper hand in the quest for top spot, needing only a draw rather than a win against Freiburg on matchday six.

It would be a huge boost. One of the best things UEFA have done in recent years, along with bringing in the Conference, is tweaking the Europa League formula to more significantly reward those who win their group.

Two games against a Champions League dropout is a tough task and an undesirable additional burden on the fixture list. Being able to skip straight past that is such a massive reward, one that is now very much in West Ham’s reach.

Just how vital that could be for West Ham is highlighted by their upcoming schedule. This was their first of 10 games in 34 days heading into the new year. It’s a relentless schedule and means nights like this and performances like this are entirely unavoidably inevitable. Clive Allen on commentary for TNT bemoaned West Ham’s lack of urgency and energy; he was right to note their absence, but it’s not something that should be pinned on clubs or players.

Something has to give. Rest and rotation is what’s required, and a low-energy, low-output performance that ends in victory is just about the ideal result in many ways. You’d like the goal to come a bit earlier, really, but that’s not the Soucek way.

The result itself is a significant one for West Ham in many ways, but the rejuvenation of Soucek is massively welcome news. This last week we’ve seen Lockdown Soucek, and Lockdown Soucek was one of the best midfielders around.

His goal today wasn’t quite as late or in truth quite so important as the winner at Burnley on the weekend, but it was a classic slice of Soucek at his most confident and committed. The ball Maxwel Cornet whipped in was tantalisingly good, but Soucek’s run was precise and his finish composed. Those runs from deep, beyond the strikers and in behind the defence, were a feature of Soucek’s play in his earlier West Ham days and this was expertly done.

On a night where few West Ham players in truth excelled, it was Soucek who looked nearest his best even before the goal. His was a sharp and precise midfield performance on a night where generally such precision was – albeit understandably – lacking.

One thing West Ham do now have in their favour for the upcoming fixture mayhem is a lack of travelling. After this sojourn to Serbia, the Hammers don’t actually now need to leave London until a Carabao clash in Liverpool on December 20. They’ve got three London derbies in the Premier League before finishing this group campaign at home to Freiburg in a game head-to-head record now means they don’t need to win and then host Wolves. Indeed, of the nine quickfire games the Hammers have coming up on this run into the start of January, that trip to Liverpool is now the only one outside London. They also host Manchester United and Brighton while travelling to Arsenal over the traditional Busy Festive Period.

With a fixture list like this, you have to be welcome for anything that makes it slightly easier. Five consecutive games – and eight out of nine – in London is one such thing. Pinching a win from a performance like this tonight is another.

A game to be ticked off and forgotten has been ticked off and forgotten.

Read More

Cash Machine: Terms & Conditions

Cash Machine: Terms & Conditions

Cash Machine Terms and Conditions

ITEM 1: COMPETITION NAME

Cash Machine running from the Start Date to the End Date as set out below (the “Competition”).

ITEM 2: PROMOTER

Bauer Media Audio Ireland LP acting by its General Partner Bauer Audio Ireland Limited, registered office: Marconi House, Digges Lane, Dublin 2, D02 TD60, Ireland and registered under limited partnership number LP3374 in association / partnership with Siteridge Ltd t/a Red FM, University Technology Centre, Curraheen Road, Bishopstown, Co Cork (the “Promoter”).

This is a Go Loud Network Competition, running across the following radio stations:

Today FM, Newstalk, 98FM, SPIN 1038, SPIN South West, Cork’s Red FM.

ITEM 3: WEBSITE

The websites shall be the following;

www.newstalk.com/win

ITEM 4: COMPETITION START DATE, END DATE AND ENTRY PERIODS

Start Date: Friday December 1st 2023 at 3:04pm

End Date: Friday December 8th  2023 at 3:00pm

The first Entry Period will open Friday December 1st 2023 at 3:04pm and close on Friday December 8th  2023 at 3:00pm.

Any entries received before the Start Date or after the End Date (as stated above) will be invalid but you may still be charged.

We reserve the right to broadcast the Competition at any time throughout each day during the broadcast schedule.

Please note that the Competition Entry Period as specified in these Competition terms and conditions are final and are not impacted by the time of broadcast of announcements advertising how to enter the Competition, which may in some circumstances be delayed.

ITEM 5: COMPETITION DETAILS

During the Entry Period, the prize amount (the “Prize”) will be announced on air. The Prize will be the winning answer and will also be the cash amount that entrants are trying to win.

We reserve the right to announce the Prize at any time during the Entry Period. We may also advertise the Prize on the respective Station’s Website, social media or via an SMS marketing message or via any other medium at our absolute discretion.

After the Entry Period has closed, one entrant from all of the valid entries will be selected by automated random draw (the “Draw”).

In order to play the Competition, the entrant must answer their phone within 5 rings. The 5 rings will be judged according to the Station audio recording (for the avoidance of doubt the sound of a “ring ring” shall count as one ring, not two). If they are not in a position to play for any reason then they will be unable to play the Competition, and no other entrant will be called.

The entrant selected may be required to talk to the presenter / programming team, and the call may be recorded and played on-air (assuming there is no breach of these terms and conditions).

The entrant who is randomly selected to play will be asked to name the Prize relevant to that Entry Period of the Competition.

If they give the correct Prize they will win. We may ask an entrant to repeat or confirm their answer.

The entrant will not win the Prize should they:

fail to answer the phone at all; or

fail to answer the phone within five rings (according to the station’s audio); or

give the incorrect Prize; or

fail to say anything at all; or

be disconnected for any reason beyond our control

Where there is any doubt in relation to whether or not an entrant has given the correct Prize or the Prize should be awarded, we reserve the right to defer decision making to an off-air adjudicator to check the audio recording with reference to these terms and conditions.

Where there has been a winner, a new Prize will be announced on-air and the pool of entries will be reset for the next Entry Period. Entrants will need to enter again to be eligible to win. All previous entries will not be valid for future Draws.

Where there has not been a winner, there will be a rollover and we reserve the right to announce a new Prize for the next Draw. The Prize will not be lower than the Prize for the previous Draw. All entries from the completed Draw, and any previous Draws, where no winner was declared, will automatically be eligible for the next Draw. Entrants do not need to enter again in order to be eligible but are able to do so if they would like to increase their chances.

We reserve the right to guarantee a winner for a Draw. This will be clearly communicated on-air throughout the Entry Period of that Draw. Where a winner is guaranteed, if the first entrant chosen to play is not declared the winner, another entrant will be drawn at random and asked to play. This process will continue until a winner is declared.

ITEM 6: ROUTES OF ENTRY AND COSTS

Entrants can enter the Competition by sending an SMS message starting with the keyword PLAY to 57557. If the message does not start with the valid Keyword(s), or is not sent to the valid number, it will not be entered. Entrants will receive an automated SMS response to their SMS message confirming their entry.

Entrants are responsible for all costs associated with entering this Competition. Texts cost €2.50 (from Ireland) + standard network rate. Entrants must have permission from the bill payer before entering the Competition.

Bauer Media Audio Ireland is not responsible for any network or technical issues an entrant may experience, such as latency of the mobile phone network, which may delay or prevent their participation or cause them to lose the Competition if on-air.

ITEM 7: ENTRANT RESTRICTIONS

The Competition is only open to people aged 18 and over who: (i) live in the Republic of Ireland, (ii) are not a Bauer employee or their immediate family (including live-in partner) and (iii) are not an employee of any third-party sponsors or prize providers, or their immediate family (including live-in partner).

You can enter each Draw a maximum of 12 times via SMS in each Friday to Friday period. Entrants must obtain permission from the bill payer before texting to enter the Competition.

We reserve the right to run bonus SMS entry incentives throughout the duration of the Competition. These incentives will be communicated via the automated SMS response received to confirm the entry.

Where we operate an incentive, the entry limit may change.

It is possible to be selected more than once to play the Competition between the Start Date and End Date, and if the entrant selected has not previously won the Prize, they are eligible to play again.

ITEM 8: WINNER ANNOUNCEMENT

Entrants who are randomly selected will be contacted by the phone number provided with their entry. This may be live on air or off-air. Due to programming schedules, this may not be broadcast on all participating radio stations.

All callers are randomly selected in the same way and any off-air recording will only ever take place after the entries have closed. The name, hometown, photo and any video or audio recording of the winner may also be posted on the Promoter’s Website and / or social media platforms.

By entering the Competition, the entrant is automatically consenting to being called and having their name and location announced on-air.

Entrants are only able to win a single prize throughout the duration of this Competition. Also, if an entrant has won €500 or more in any Bauer Media Competition over the past 6 months they are not eligible to win.

ITEM 9: PRIZE DETAILS

The Prize will always be a cash amount that will be delivered to a winner paid in cash, by bank transfer or by cheque.

Delivery or payment of the Prize is subject to the winner providing personal identification and / or proof of address and to internal compliance checks. The Prize is non-transferable and cannot be exchanged. Payment of the Prize may take up to 28 days from the point at which the Promoter receives the correct details.

Where, it emerges after the Prize has been awarded that the entrant was in breach of these terms and conditions, we reserve the right to withdraw the Prize from that winner and they will not be entitled to any further reward or remuneration. We reserve the right to exclude individuals who breach our terms and conditions from entering our competitions.

ITEM 10: INTELLECTUAL PROPERTY AND CONSENT

We will sometimes (at our discretion) telephone entrants and ask them to speak on-air. They have the right to refuse. If they consent, their voice will be recorded and they consent to this recording being used on our radio broadcasts. Entrants agree that we will own this recording and that a copy of it will be stored for further exploitation, which may include promotion.

Entrants will not be put through to speak on-air if we think they are driving illegally, intoxicated, likely to swear, or otherwise offend our listeners. Whilst on air for the purposes of this competition entrants must not use foul language, swear, say or do anything defamatory or illegal or say or do anything which would damage the reputation of the Promoter, is offensive or inappropriate or which would cause us, or our listeners, harm. Failure to comply will result in disqualification, and if the entrant has won the prize, this will be forfeited.

ITEM 11: OTHER CONDITIONS

We will only accept entries that comply with our terms and conditions and we may disqualify the entrant if we know or suspect that they have breached them. All our decisions relating to the Competition and/or awarding of prizes are final. No discussions or correspondence with entrants or any other person will be entered into about the operation of this Competition. We have the right to cancel, amend, terminate or suspend this Competition if forced to do so due to circumstances outside our control.

From time to time we may offer 3 for 2 or 4 for 2 offers. These are discretionary and maybe be reinstated or removed without notice. They will only be publicized via the confirmation text from a valid entry.

ITEM 12: DATA PROTECTION

When entering the Cash Machine competition entrants are add to our customer database and may receive service-related SMS messages,  these messages will be free of charge.  Entrants can opt out of this at any time by texting: STOP to 57557. This will be charged at 1 standard network rate message or entrants may also optout of receiving service-related SMS messages by visiting https://oo.fonix.com/gl and entering their mobile number.

If entrants do not wish to receive any service-related communications, they will need to do this after each time they re-enter the Competition. Entrants’ personal data will (regardless of whether they opt-out) always be used to process their entry.

You may also like to review our Privacy Policy,  this outlines how we process any personal data we collect from our entrants. https://www.newstalk.com/privacy-policy

ITEM 13: CODE OF CONDUCT

The promoter reserves the right to disqualify an entrant from entering future competitions if their conduct is contrary to the spirit or intention of the competition.  Any entrant deemed to be rude or offensive to our staff or other entrants on social media, telephone, electronic communications, post or in person will be disqualified from entry and may ultimately be banned from future entry to promotions.

ITEM 14: CONTACT DETAILS

The promoter of this Competition is Bauer Media Audio Ireland LP acting by its General Partner Bauer Audio Ireland Limited, registered office: Marconi House, Digges Lane, Dublin 2, D02 TD60, Ireland and registered under limited partnership number LP3374 in association / partnership with Siteridge Ltd t/a Red FM, University Technology Centre, Curraheen Road, Bishopstown, Co Cork (the “Promoter”)

This is a Go Loud Network Competition, running across the following radio stations:

Today FM, Newstalk, 98FM, SPIN 1038, SPIN South West, Cork’s Red FM.

For customer support or any queries, please email [email protected]

Read More

OGRA jacks up LPG price by Rs4/kg for December

OGRA jacks up LPG price by Rs4/kg for December

ISLSMABAD: The Oil and Gas Regulatory Authority (OGRA) has increased the price of Liquefied Petroleum Gas (LPG) by approximately Rs4 per kilo gram for the month of December 2024 and issued a notification in this regard.

According to the notification, OGRA has increased the LPG price by Rs3.82 per Kilo Gram and due to this price hike, domestic cylinder increased by Rs45 and commercial cylinder by Rs174 and new price of LPG per kg will be Rs254.86 from December 1.

The new domestic LPG cylinder price has been fixed at Rs3,735, as per kg of LPG has increased by Rs3.82 paise.

As per OGRA notification, now LPG will be available at Rs255 per kg instead of Rs251 per kg, domestic cylinder will be available at Rs3,007 instead of Rs2962, commercial cylinder will be available at Rs11,571 instead of Rs11,397.

LPG Industries Association Pakistan Chairman Irfan Khokhar said that the crisis of natural gas has intensified across the country. In most areas of the country even cooking has become difficult. LPG is the only cheap fuel capable of meeting the shortage of natural gas.

At present there is a daily production of 2000 metric tonnes of LPG across the country while the local consumption has crossed 5000 tonnes. 60% of domestic demand is dependent on imported LPG. Bad policies and high taxes have adversely affected the LPG industry, said Chairman LPG Industries Association Pakistan.

LPG distributors pay billions of rupees in tax. LPG should be made tax free and unnecessary taxes on LPG should be abolished like LNG. If LPG industry is treated like LNG, we will provide LPG to every house at a lower price than to sui gas price, said Irfan Khokhar, Chairman LPG Industries Association Pakistan.

Ahmad Ahmadani

Read More